Farouq Qaqish
Family Medicine · Omaha, NENPI 1821148826
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 27.5% of the total. Reporting peaked in 2022 at $2,004 and has fallen 66.8% since, to $665 in 2023. Among family medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$950
- Amgen$824
- AbbVie$727
- Bayer$337
- Lilly USA, LLC$256
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,543100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $1,799 |
| Novo Nordisk | 84 | $950 |
| Amgen | 38 | $824 |
| AbbVie(2 entities) | 48 | $727 |
| Bayer | 16 | $337 |
| Lilly USA, LLC | 22 | $256 |
| Amarin Pharma, Inc. | 13 | $189 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $145 |
| Johnson & Johnson(2 entities) | 9 | $140 |
| Mayne Pharma Commercial LLC | 1 | $125 |
| Genentech USA, Inc. | 6 | $102 |
| Biohaven Pharmaceuticals, Inc. | 4 | $82 |
| Pfizer | 6 | $81 |
| Ironshore Pharmaceuticals Inc. | 1 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $79 |
| GSK | 6 | $79 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| Kowa Pharmaceuticals America, Inc. | 4 | $50 |
| Abbott | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Eisai Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Novartis | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Boston Scientific | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,543 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 14 | $111 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Omaha
- Gerard StanleyOmaha$50K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
- Christopher ConnollyOmaha$12K
- Paul VanaOmaha$12K
- Stephen TetraultOmaha$11K
- James RamigOmaha$11K
- Jeffrey RappOmaha$10K
- Christine Carlson RahnOmaha$10K
- Joseph DumbaOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.